Search results for " brain"

showing 10 items of 985 documents

Improvement of phonemic fluency following leftward prism adaptation.

2021

AbstractAnatomo functional studies of prism adaptation (PA) have been shown to modulate a brain frontal-parieto-temporal network, increasing activation of this network in the hemisphere ipsilateral to the side of prism deviation. This effect raises the hypothesis that left prism adaptation, modulating frontal areas of the left hemisphere, could modify subjects’ performance on linguistic tasks that map on those areas. To test this hypothesis, 51 healthy subjects participated in experiments in which leftward or rightward prism adaptation were applied before the execution of a phonemic fluency task, i.e., a task with strict left hemispheric lateralization onto frontal areas. Results showed tha…

Adultmedicine.medical_specialtygenetic structuresScienceAudiology050105 experimental psychologyLateralization of brain functionFunctional LateralityArticle03 medical and health sciencesFluency0302 clinical medicinemedicinePrism adaptation (PA) phonological neurologicalHumans0501 psychology and cognitive sciencesAttentionFunctional studiesLanguageMultidisciplinaryLanguage abilitySettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaQ05 social sciencesRHealthy subjectsBrainAdaptation PhysiologicalCognitive controlVisual PerceptionMedicineFemalePrismPsychologyPrism adaptation030217 neurology & neurosurgeryPsychomotor PerformanceScientific reports
researchProduct

Brainstem reflex circuits revisited

2004

Our current understanding of brainstem reflex physiology comes chiefly from the classic anatomical-functional correlation studies that traced the central circuits underlying brainstem reflexes and establishing reflex abnormalities as markers for specific areas of lesion. These studies nevertheless had the disadvantage of deriving from post-mortem findings in only a few patients. We developed a voxel-based model of the human brainstem designed to import and normalize MRIs, select groups of patients with or without a given dysfunction, compare their MRIs statistically, and construct three-plane maps showing the statistical probability of lesion. Using this method, we studied 180 patients with…

Adult; Aged; 80 and over; Blinking; Brain Stem Infarctions; diagnosis/physiopathology; Brain Stem; physiopathology; Electromyography; Female; Humans; Jaw; Magnetic Resonance Imaging; Male; Masseter Muscle; Middle Aged; Reflex; AbnormalAdultMalemedicine.medical_specialtyBrain Stem InfarctionsClinical neurophysiologyReflex80 and overmedicineHumansCorneal reflexAgedAged 80 and overBlinkingReflex AbnormalElectromyographyMasseter MuscleDental occlusionAnatomyMiddle AgedMagnetic Resonance Imagingdiagnosis/physiopathologyPonsJawCiliospinal reflexAbnormalReflexFemaleNeurology (clinical)BrainstemphysiopathologyPsychologyJaw jerk reflexBrain StemBrain
researchProduct

Pattern of brain destruction in Parkinson's and Alzheimer's diseases

1996

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common age-related degenerative disorders of the human brain. Both diseases involve multiple neuronal systems and are the consequences of cytoskeletal abnormalities which gradually develop in only a small number of neuronal types. In AD, susceptible neurons produce neurofibrillary tangles (NFTs) and neuropil threads (NTs), while in PD, they develop Lewy bodies (LBs) and Lewy neurites (LNs). The specific lesional pattern of both illnesses accrues slowly over time and remains remarkably consistent across cases. In AD, six developmental stages can be distinguished on account of the predictable manner in which the neurofibrillar…

AgingPathologymedicine.medical_specialtyParkinson's diseaseModels NeurologicalLimbic systemAlzheimer DiseaseLimbic SystemmedicineHumansBiological PsychiatryNeocortexLewy bodyBrainParkinson DiseaseNeurofibrillary tangleHuman brainmedicine.diseasePsychiatry and Mental healthmedicine.anatomical_structurenervous systemNeurologyCerebral cortexLewy neuriteNeurology (clinical)PsychologyNeuroscienceJournal of Neural Transmission
researchProduct

Alzheimer’s disease and infections, where we stand and where we go

2014

Editorial Alzheimer’s disease (AD) is a progressive neurological disorder, which represents the most common form of dementia, one of the major causes of disability in later life. Age is the greatest risk factor for AD, which typically affects people aged 65 years and over, with an age-standardised prevalence of 4.4 [1]. However, AD is not a normal part of ageing and advanced age alone does not justify the disease. Several pathways have been implicated in AD pathophysiology, the most described is the neurodegenerative one, which lead to the brain accumulation of beta-amyloid and neurofibrillary tangles, aggregations of hyperphosphorylated tau protein, macroscopically resulting in brain atrop…

AgingTraumatic brain injuryImmunologyTau proteinperiodontal diseaseDiseaseInfectionsBioinformaticsAtrophyAlzheimer'MedicineDementiaRisk factorAlzheimer's; infections; herpes viruses; periodontal disease; infectionInflammationSettore MED/04 - Patologia Generalebiologybusiness.industryVascular diseaseHerpes virusesOdds ratiomedicine.diseaseinfectionAgeingEditorialImmunologybiology.proteinherpes viruseSettore MED/26 - NeurologiabusinessAlzheimer’s diseaseImmunity & Ageing
researchProduct

Synthesis and Characterization of a Novel Series of Agonist Compounds as Potential Radiopharmaceuticals for Imaging Dopamine D-2/3 Receptors in Their…

2014

Imaging of dopamine D2/3 receptors (D2/3R) can shed light on the nature of several neuropsychiatric disorders in which dysregulation of D2/3R signaling is involved. Agonist D2/3 tracers for PET/SPECT imaging are considered to be superior to antagonists because they are more sensitive to dopamine concentrations and may selectively label the high-affinity receptor state. Carbon-11-labeled D2/3R agonists have been developed, but these short-lived tracers can be used only in centers with a cyclotron. Here, we report the development of a series of novel D2R agonist compounds based on the 2-aminomethylchromane (AMC) scaffold that provides ample opportunities for the introduction of longer-lived […

AgonistD-3 RECEPTORPHARMACOPHOREChemistrymedicine.drug_classDERIVATIVESPharmacologyIN-VIVO ACTIVITYHUMAN BRAINRadioligand AssayANTERIOR-PITUITARYPOSITRON-EMISSION-TOMOGRAPHYENDOGENOUS DOPAMINEIn vivoDopamineSpect imagingDopamine receptor D2Drug DiscoveryLIGAND-BINDINGmedicineMolecular MedicineReceptorAGENTSEndogenous agonistmedicine.drugJournal of Medicinal Chemistry
researchProduct

Intra-Nasally Administered Oligopeptide Lunasin Acts as a Possible Anti-Psychotic Agent in Mice Models

2019

Background and Objectives: Previously we have shown that synthetic lunasin, a 43 amino acid residue-containing peptide, after its central (intracisternal) administration in mice demonstrated antagonism against dopaminergic drug behavioural effects, indicating a putative antipsychotic/anti-schizophrenic profile of lunasin. The aims of the present studies were: to test whether lunasin would show an influence on the dopaminergic system after intranasal administration, and to examine the effect(s) of lunasin on serotonin and glutamatergic systems, which could play an essential role in antipsychotic action. Materials and Methods: Lunasin was administered intra-nasally at doses 0.1 and 1 nmol/mou…

AgonistMedicine (General)medicine.drug_classreceptor bindingbrain monoaminesPharmacologyMotor ActivityLunasinArticleintranasal administration03 medical and health sciencesMiceR5-9200302 clinical medicinehyper-locomotionmedicineAnimalslunasin; intranasal administration; hyper-locomotion; brain monoamines; receptor bindingAmphetaminePhencyclidine5-HT receptorAdministration IntranasalMice Inbred ICRChemistrylunasinAmphetaminesGeneral MedicineDisease Models AnimalMonoamine neurotransmitter030220 oncology & carcinogenesisNMDA receptorSerotoninOligopeptides030217 neurology & neurosurgerymedicine.drugAntipsychotic AgentsMedicina; Volume 55; Issue 7; Pages: 393
researchProduct

Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease

2010

Amyloid aggregates play a major role in the development of Alzheimer's disease. Targeting these aggregates by PET probes enables non-invasively the detection and quantification of amyloid deposit distribution in human brains. Based on benzothiazole core structure a series of amyloid imaging agents were developed. Currently [(11)C]2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (Pittsburgh Compound-B (PIB) is the most specific and widely used amyloid imaging ligand. But due to the short half life of (11)C, longer lived (18)F-labeled derivatives offer logistic advantages and higher contrast images. In this work, three different [(18)F]fluoroethoxy-substituted benzothiazole derivatives ([(18…

AmyloidFluorine RadioisotopesAmyloidStereochemistryPlaque AmyloidAmyloid plaquesMice SCIDScid miceMicechemistry.chemical_compoundAlzheimer DiseasemedicineAnimalsBenzothiazolesRadiationChemistryBrainHuman brainAlzheimer's diseasemedicine.diseaseLigand (biochemistry)Fluorine-18PETmedicine.anatomical_structureBenzothiazolePositron-Emission TomographyLipophilicityRadiopharmaceuticalsAlzheimer's diseasePreclinical imagingApplied Radiation and Isotopes
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases.

2013

Resveratrol-a natural polyphenolic compound-was first discovered in the 1940s. Although initially used for cancer therapy, it has shown beneficial effects against most cardiovascular and cerebrovascular diseases. A large part of these effects are related to its antioxidant properties. Here we review: (a) the sources, the metabolism, and the bioavailability of resveratrol; (b) the ability of resveratrol to modulate redox signalling and to interact with multiple molecular targets of diverse intracellular pathways; (c) its protective effects against oxidative damage in cardio-cerebro-vascular districts and metabolic disorders such as diabetes; and (d) the evidence for its efficacy and toxicity…

Antioxidantmedicine.medical_treatmentBiological AvailabilityPharmacologyResveratrolBiologyToxicologymedicine.disease_causeAntioxidantsNitric oxidechemistry.chemical_compoundMetabolic DiseasesDiabetes mellitusStilbenesOxidative stress antioxidant brain cardiovascular diabetes nitric oxideDiabetes MellitusmedicineHumansClinical Trials as Topicfood and beveragesGeneral Medicinemedicine.diseaseBioavailabilityCerebrovascular DisordersOxidative StresschemistryCardiovascular DiseasesResveratrolToxicityOxidation-ReductionOxidative stressIntracellularFood Science
researchProduct

Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model.

2012

Background The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood. Methodology/Principal Findings In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytome…

Apolipoprotein EDrugs and DevicesDrug Research and DevelopmentLipoproteinsMaterials Sciencelcsh:MedicinePlasma protein bindingBiologyBlood–brain barrierBiochemistryFlow cytometryApolipoproteins EMaterial by AttributeMiceApolipoproteins EDrug Delivery Systemsddc:570Cell Line TumormedicineAnimalsHumansNanotechnologyPharmacokineticsReceptorlcsh:ScienceBiologySerum AlbuminBrain DiseasesMultidisciplinaryMicroscopy Confocalmedicine.diagnostic_testlcsh:RBrainEndothelial CellsProteinsBiological TransportFlow CytometryCell biologymedicine.anatomical_structureBlood-Brain BarrierNanoparticles for drug delivery to the brainLDL receptorNanoparticlesMedicinelcsh:QProtein BindingResearch ArticleBiotechnologyPLoS ONE
researchProduct